Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry. This solution includes (1) a panel of highly diverse synthetic naïve antibody phage display libraries, (2) several target class specific antibody phage display libraries against difficult-to-drug targets, (3) a Twist Antibody Optimization (TAO) platform for antibody affinity and developability optimization and (4) a high-throughput antibody expression service. To highlight the power of this platform, our anti-SARS-CoV-2 antibody discovery and optimization efforts will be presented.

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.